C De Ciuceis1, F Amiri, M Iglarz, J S Cohn, R M Touyz, E L Schiffrin. 1. Vascular and Hypertension Research Unit, Lady Davis Institute for Medical Research, Sir Mortimer B Davis-Jewish General Hospital, Montreal, Quebec, Canada.
Abstract
BACKGROUND AND PURPOSE: Protective cardiovascular effects of peroxisome proliferator activated receptor (PPAR)alpha and PPARgamma activators have been demonstrated. If used as vasoprotective agents in high risk vascular patients rather than for their metabolic benefits, these agents could be associated with unwanted side effects. As a proof of concept to support the use of combined low doses of PPARalpha and PPARgamma as vascular protective agents in high risk vascular patients, we tested the hypothesis that combined low doses of PPARalpha (fenofibrate) and PPARgamma (rosiglitazone) activators would provide vascular protective benefits similar to full individual doses of these PPAR agonists. EXPERIMENTAL APPROACH: Male Sprague-Dawley rats infused with Ang II (120 ng kg(-1) min(-1)) were treated with rosiglitazone (1 or 2 mg kg(-1) day(-1)) alone or concomitantly with fenofibrate (30 mg kg(-1) day(-1)) for 7 days. Thereafter, vessels was assessed on a pressurized myograph, while NAD(P)H oxidase activity was determined by lucigenin chemiluminescence. Inflammation was evaluated using ELISA for NFkappaB and Western blotting for adhesion molecules. KEY RESULTS: Ang II-induced blood pressure increase, impaired acetylcholine-induced vasorelaxation, altered vascular structure, and enhanced vascular NAD(P)H oxidase activity and inflammation were significantly reduced by low dose rosiglitazone+fenofibrate. CONCLUSIONS AND IMPLICATIONS: Combined low doses of PPARalpha and PPARgamma activators attenuated development of hypertension, corrected vascular structural abnormalities, improved endothelial function, oxidative stress, and vascular inflammation. These agents used in low-dose combination have synergistic vascular protective effects. The clinical effects of combined low-dose PPARalpha and PPARgamma activators as vascular protective therapy, potentially with reduced side-effects and drug interactions, should be assessed.
BACKGROUND AND PURPOSE: Protective cardiovascular effects of peroxisome proliferator activated receptor (PPAR)alpha and PPARgamma activators have been demonstrated. If used as vasoprotective agents in high risk vascular patients rather than for their metabolic benefits, these agents could be associated with unwanted side effects. As a proof of concept to support the use of combined low doses of PPARalpha and PPARgamma as vascular protective agents in high risk vascular patients, we tested the hypothesis that combined low doses of PPARalpha (fenofibrate) and PPARgamma (rosiglitazone) activators would provide vascular protective benefits similar to full individual doses of these PPAR agonists. EXPERIMENTAL APPROACH: Male Sprague-Dawley rats infused with Ang II (120 ng kg(-1) min(-1)) were treated with rosiglitazone (1 or 2 mg kg(-1) day(-1)) alone or concomitantly with fenofibrate (30 mg kg(-1) day(-1)) for 7 days. Thereafter, vessels was assessed on a pressurized myograph, while NAD(P)H oxidase activity was determined by lucigenin chemiluminescence. Inflammation was evaluated using ELISA for NFkappaB and Western blotting for adhesion molecules. KEY RESULTS:Ang II-induced blood pressure increase, impaired acetylcholine-induced vasorelaxation, altered vascular structure, and enhanced vascular NAD(P)H oxidase activity and inflammation were significantly reduced by low dose rosiglitazone+fenofibrate. CONCLUSIONS AND IMPLICATIONS: Combined low doses of PPARalpha and PPARgamma activators attenuated development of hypertension, corrected vascular structural abnormalities, improved endothelial function, oxidative stress, and vascular inflammation. These agents used in low-dose combination have synergistic vascular protective effects. The clinical effects of combined low-dose PPARalpha and PPARgamma activators as vascular protective therapy, potentially with reduced side-effects and drug interactions, should be assessed.
Authors: A Susanne M Zadelaar; Lianne S M Boesten; J Wouter Jukema; Bart J M van Vlijmen; Teake Kooistra; Jef J Emeis; Erik Lundholm; German Camejo; Louis M Havekes Journal: Arterioscler Thromb Vasc Biol Date: 2006-08-24 Impact factor: 8.311
Authors: P Delerive; K De Bosscher; S Besnard; W Vanden Berghe; J M Peters; F J Gonzalez; J C Fruchart; A Tedgui; G Haegeman; B Staels Journal: J Biol Chem Date: 1999-11-05 Impact factor: 5.157
Authors: Ulrich Kintscher; Christopher Lyon; Shu Wakino; Dennis Bruemmer; Xu Feng; Stephan Goetze; Kristof Graf; Aristidis Moustakas; Bart Staels; Eckart Fleck; Willa A Hsueh; Ronald E Law Journal: Circ Res Date: 2002-11-29 Impact factor: 17.367
Authors: Quy N Diep; Mohammed El Mabrouk; Jeffrey S Cohn; Dierk Endemann; Farhad Amiri; Agostino Virdis; Mario Fritsch Neves; Ernesto L Schiffrin Journal: Circulation Date: 2002-05-14 Impact factor: 29.690
Authors: Rhian M Touyz; Christian Deschepper; Jeong Bae Park; Gang He; Xin Chen; Mario Fritsch T Neves; Agostino Virdis; Ernesto L Schiffrin Journal: J Hypertens Date: 2002-06 Impact factor: 4.844
Authors: Petra Haberzettl; James P McCracken; Aruni Bhatnagar; Daniel J Conklin Journal: Am J Physiol Heart Circ Physiol Date: 2016-03-25 Impact factor: 4.733
Authors: Marcia Venegas-Pont; Julio C Sartori-Valinotti; Christine Maric; Lorraine C Racusen; Porter H Glover; Gerald R McLemore; Allison V Jones; Jane F Reckelhoff; Michael J Ryan Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-02-04 Impact factor: 3.619